KOREA/EU CLOSE TO AGREEMENT ON PHARMA DEAL

13 December 1993

The Korea Foreign Trade Association and the European Commission, meeting in Seoul last month, expressed the hope that South Korea will harmonize duties on various products from the European Union and allow the EU's member countries to participate in the pharmaceutical sector.

Representing the EU, Vice President and Commissioner for external economic relations, Sir Leon Brittan, called for tariff cuts on imports from the EU and said that "we need a commitment from South Korea that no duty will be higher than, say, 20%, so that European products can more easily access the Korean market." He also urged Korea to relax some of its established restrictions on the conduct of business, in order to give all partners access to the internal process of liberalization.

Korea's Foreign Minister Han Sung-joo and Commissioner Brittan also agreed to form a Korea/EU "wisemen's club," to study ways to promote ties between the two regions towards the 21st century, and Mr Han asked EU countries to permit Korea to retain its generalized system of preference status until the country joins the Organization of Economic Cooperation and Development in early-1996.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight